Background
Aim
Background and rationale
Objective
Methods
Criteria for inclusion in this review
Types of studies
Types of participants
Types of interventions
Inclusions
Exclusions
Types of outcome measures
A. Women's observations (subjective measures)
-
Perception of cure and improvement
B. Quantification of symptoms (objective measures)
-
Pad changes over 24 hours (self-reported)
-
Incontinent episodes over 24 hours (self-completed bladder chart)
-
Pad tests of quantified leakage (mean volume or weight of urine loss)
C. Clinician's observations
-
Objective assessment of pelvic floor muscle strength
D. Quality of life
-
General health status measures (physical, psychological, other)
-
Condition-specific health measures (specific instruments designed to assess incontinence)
E. Socioeconomic measures
-
Health economic measures
Search strategy
Eligibility criteria
Study selection
Assessment of methodological quality
Level of evidence
Methodological quality
Data extraction
-
Information about service delivery (health professional and setting/institution)
-
Demographic information about the subjects in the study
-
Study methods
-
Descriptions of the intervention(s)
-
Description of the outcome measure(s)
-
Key results from data analysis – short term and at 12 months
Data synthesis
Results
Methodological quality and description of studies
Studies | Intervention | Hierarchy of Evidence a
| Quality Rating Score (%) | Mean age (SD)b
|
---|---|---|---|---|
Bo (1999) | PFMT v BF v ES v control | II | 23/23 (100) | 49.6 (10) |
Morkved (2002) | PFMT v PFMT+BF | II | 22/23 (96) | 47.8 (8.2) |
Dumoulin (2004) | PFMT+ES+BF v PFMT+ES+BF+Ab Ex v control | II | 21/23 (91) | 36.2 (median) (IQ range 23–39) |
Bo (2000) | PFMT | II | 21/23 (91) | 49.6 (10) |
Berghmans (1996) | PFMT v PFMT+BF | II | 20/23 (87) | 48 (range 18–70) |
Knight (1998) | PFMT+BF v PFMT+BF+ES('home') v PFMT+BF+ES('clinic') | II | 17/23 (74) | NR (range 24–68) |
Miller (1998b) | PFMT (motor learning) | II | 17/23 (74) | 68.4 (range 60–84) |
Parkkinen (2004) | PFMT+ES+BF+VW v PFMT+VW | III-2 | 14/19 (74) | 46.8 (range 32–65) |
Wong (2001) | PFMT+BF v PFMT+BF+Ab BF | II | 16/23 (70) | 46 (range 30–62) |
Dumoulin (1995) | PFMT+ES+BF | IV | 13/19 (68) | 32 (9.5) |
Johnson (2001) | PFMT (SVC) v PFMT (NMVC) | II | 15/23 (65) | 50 (35–65) |
Hay-Smith (2002) A | PFMT (motor learning/strength) v PFMT (motor learning) | II | 15/23 (65) | 48.8 (13.2 SD) |
Arvonen (2001) | PFMT v PFMT+VW | II | 15/23 (65) | 48 (range 28–65) |
Cammu & van Nylen (1998) | PFMT+BF v VW | II | 15/23 (65) | 55.9 (9.5) |
Turkan (2005) | PFMT+ES | III-2 | 11/19 (58) | 47.6 (8) |
Pieber (1995) | PFMT+BF v PFMT+BF+VW | II | 13/23 (57) | 43 (+/- 6) |
Chen (1999) | PFMT+ES | IV | 11/19 (58) | NS (range 20 to >50) |
Glavind (1996) | PFMT v PFMT+BF | II | 13/23 (57) | 45 (median)(range 40–48) |
Pages (2001) | PFMT v BF | II | 13/23 (57) | 51.1 (range 27–80) |
Bidmead (2002) A | PFMT v PFMT+ES v PFMT+sham ES v control | II | 10/23 (43) | NR |
Sung (2000) | PFMT | III-2 | 8/19 (42) | range 18 – >60 |
Aksac (2003) | PFMT v PFMT+BF v control | II | 9/23 (39) | 52.9 (7.2) |
Balmforth (2004) A | PFMT+BF | IV | 6/19 (32) | 49.5 (10.6) |
Finkenhagen (1998) A | PFMT | IV | 5/19 (26) | 49 (range 25–67) |
Studies | Diagnosis | Intervention by | Setting | Excluded if prior surgery | Volunteers (V) or Referred (R) |
---|---|---|---|---|---|
Bo (1999) | S, Pad T, UDS | PT | Multicentre | yes | V+R |
Morkved (2002) | S, Pad T, UDS | PT | NR | yes | V |
Dumoulin (2004) | S, Pad T, UDS | PT | NR | yes | V |
Bo (2000) | S, Pad T, UDS | PT | NR | yes | NR |
Berghmans (1996) | S, CST, Pad T, UDS | PT | PT clinic | yes | R |
Knight (1998) | UDS | PT | Tertiary Clinic | no | NR |
Miller (1998) | S, CST | NR | NR | yes | NR |
Parkkinen (2004) | S, Pad T, UDS | PT | Hospital PT clinic | no | NR |
Wong (2001) | S, UDS | PT | Hospital PT clinic | yes | R |
Dumoulin (1995) | S, Pad T, UDS | PT | NR | NR | V |
Johnson (2001) | S, UDS | NR | NR | yes | V+R |
Hay-Smith (2002) | S, CST, Pad T | PT | NR | yes | V+R |
Arvonen (2001) | S | PT | OP PT clinic | no | R |
Cammu & van Nylen (1998) | S, UDS | PT | NR | no | NR |
Turkan (2005) | S, Pad T, UDS | PT | University PT clinic | yes | R |
Pieber (1995) | UDS | PT | Urodynamic unit | yes | R |
Chen (1999) | S, CST, Pad T, UDS | NR | NR | yes | R |
Glavind (1996) | S, Pad T, UDS | NR | NR | yes | NR |
Pages (2001) | S, UDS | PT | OP hospital clinic | no | R |
Bidmead (2002) | UDS | PT | NR | NR | NR |
Sung (2000) | S | PT | NR | NR | R |
Aksac (2003) | UDS | Therapist | NR | NR | NR |
Balmforth (2004) | S, UDS | PT | NR | yes | R |
Finkenhagen (1998) | NR | PT | PT clinic (primary care) | NR | NR |
• Hierarchy of evidence
• Methodological quality of included studies
Types of participants
Identification and/or control of potential confounders
Study | IE/day | IE/week | Urine loss (g) (pad test) |
---|---|---|---|
Aksac (2003) | 20 (1 hour) | ||
Arvonen (2001) | 25 (SPT, st.b.vl) | ||
Balmforth (2004) | 12.2 (SPT, st.b.vl) | ||
Berghmans (1996) | 2–3 | 28 (48 hr pad test) | |
Bidmead (2002) | 10 (SPT) | ||
Bo (1999) | 2.0 per 3 days | 38.6 (SPT, st.b.vl.); 14.5 (24 hr pad test) | |
Bo (2000) | 45 (SPT, st.b.vl) | ||
Cammu & van Nylen (1998) | 14.4 | NR | |
Chen (1999) | 5.5 | 20 (1 hour) | |
Dumoulin (1995) | 74.4 (SD 84.3) (SPT, st.b.vl) | ||
Dumoulin (2004) | PF group: 12.5 g: PF+ abs group: 20 g (SPT, st.b.vl) | ||
Finkenhagen (1998) | NR | ||
Glavind (1996) | 10.9 (SPT, st.b.vl) | ||
Hay-Smith (2002) | 1.8 | 3.9 ml (paper towel test) | |
Johnson (2001) | 3.6 (range: 1.86–13) | 12.9 (range: 1.76–111.42) (10 hour pad test) | |
Knight (1998) | 14.6 (SPT, st.b.vl) | ||
Miller (1998) | Paper towel test | ||
Morkved (2002) | 27.5 (SPT, st.b.vl), 42.2 (48 hr pad test) | ||
Pages (2001) | NR | ||
Parkkinen (2004) | (SPT, st.b.vl) | ||
Pieber (1995) | NR | ||
Sung (2000) | NR | ||
Turkan (2005) | (1) 8.6 (2) 29.1 (3) 236.4) (1 hour pad test) | ||
Wong (2001) | 6.3 | 10.8 (SPT, standardised fluid intake) |
Types of interventions
PFMT studies | Treatment time | N (subjects) | N (% lost to follow-up) | % cure | % cure/improved | N (%) positive & statistically significant outcomes |
---|---|---|---|---|---|---|
Bo (1999) | 6 months | 29 | 4 (14) | 44 (1), 56 (4) | 48 (4) | 8/9 (89) |
Morkved (2002) | 6 months | 50 | 4 (17) | 46 (1), 30 (4) 57 (2) | 93 (4) | 6 (100) |
Bo (2000) | 6 months | 24 | 4 (8) | 6–44 (5) | NR | 1 (100) |
Berghmans (1996) | 4 weeks | 20 | 0 (0) | 15 (2) | 85 (2) | 1 (100) |
Miller (1998b) | 1 week | 27 | 0 (0) | 23 (3) | NR | 2 (100) |
Hay-Smith (2002)a
| 20 weeks | 64 | 2 (3) | 7 (4) | 47 (4) | NR |
Hay-Smith (2002)b
| 20 weeks | 64 | 3 (5) | 2 (4) | 41 (4) | NR |
Arvonen (2001) | 4 months | 20 | 1 (5) | 26 (1) | 58 (4) | 3 (100) |
Glavind (1996) | NR (2–3 sessions) | 20 | 5 (25) | 20 (1) | NR | NR |
Pages (2001) | 3 months | 27 | 0 (0) | 69 (4) | 100 (4) | 3 (100) |
Bidmead (2002) | 14 weeks | 40 | NR | NR | NR | 3 (100) |
Sung (2000) | 6 weeks | 30 | NR | NR | NR | 3 (100) |
Aksac (2003) | 8 weeks | 20 | NR | 75 (3) | 100 (3) | 10 (100) |
Finkenhagen (1998) | 6 months | 38 | 2 (5) | 35 (4) | 71 (4) | NR |
PFMT+BF studies | Treatment time | N (subjects) | N (% lost to follow-up) | % cure | % cure/improved | N (%) positive & statistically significant outcomes |
---|---|---|---|---|---|---|
Morkved (2002) | 6 months | 53 | 5 (9) | 58 (1); 65 (2) 40 (3) | 97 (3) | 6 (100) |
Berghmans (1996) | 4 weeks | 20 | 0 (0) | 25 (2) | 95 (2) | 1 (100) |
Knight (1998) | 6 months | 21 | 3 (14) | NR | 72 (1) 56 (3) | 2 (100) |
Wong (2001) a
| 4 weeks | 19 | 0 (0) | NR | NR | 3/5 (60) |
Wong (2001)b
| 4 weeks | 19 | 0 (0) | NR | NR | 4/5 (80) |
Johnson (2001) a
| 6 weeks | 16 | 0 (0) | 25 (3) | NR | 4 (100) |
Johnson (2001) b
| 6 weeks | 16 | 0 (0) | 38 (3) | NR | 2/4 (80) |
Cammu & van Nylen (1998) | 12 weeks | 30 | 0 (0) | 53 (3) | NR | NR |
Pieber (1995) | 3 months | 25 | 11 (44) | 22 (3) | 86(4) | NR |
Glavind (1996) | 4 weeks | 20 | 1 (5) | 58 (4) | NR | NR |
Pages (2001) | 1 month | 24 | 11 (46) | 62 (3) | 100 (3) | 1 (100) |
Aksac (2003) | 8 weeks | 20 | NR | 80 (4) | 100 (4) | 8 (100) |
Balmforth (2004) | 14 weeks | 97 | NR | NR | NR | 5 (100) |
PFMT+ES studies | Treatment time | N (subjects) | N (% lost to follow-up) | % cure | % cure/improved | N (%) positive & statistically significant outcomes |
---|---|---|---|---|---|---|
Turkan (2005) | 5 weeks | 17 | 0 (0) | Total: 38 (1) a: 88; b: 1; c: 0 | NR | 4 (100) |
Chen (1999) | 3 months intensive, 21 m home training | 72 | 0 (0) | 7 (2) | 61 (2) | NR |
Bidmead (2004) | 14 weeks | 97 | NR | NR | NR | 3 (100) |
PFMT+VW studies | Treatment time | N (subjects) | N (% lost to follow-up) | % cure | % cure/improved | N (%) positive & statistically significant outcomes |
---|---|---|---|---|---|---|
Parkkinen (2004) | 12 months | 19 | 3 (16) | NR a
| NR a
| 3 (100) |
Arvonen (2001) | 4 months | 20 | 2 (10) | 50 (1); 22 (2) | 61 (2) | 2 (100) |
PFMT+ES+BF studies | Treatment time | N (subjects) | N (% lost to follow-up) | % cure | % cure/improved | N (%) positive & statistically significant outcomes |
---|---|---|---|---|---|---|
Dumoulin (2004) a
| 8 weeks | 21 | 1 (5) | 70 (1) | 90 (1) | 8/9 (89) |
Dumoulin (2004) b
| 8 weeks | 23 | 0 (0) | 73 (1) | 90 (1) | 8/9 (89) |
Knight (1998) a
| 6 months | 25 | 6 (24) | NR | 53 (1) 47 (2) | 2 (100) |
Knight (1998) b
| 6 months | 24 | 4 (17) | NR | 80 (1) 80 (2) | 2 (100) |
Dumoulin (1995) | 3 weeks | 10 | 2 (20) | 62.5 (1) | 100 (1) | 3 (100) |
PFMT+BF+VW studies | Treatment time | N (subjects) | N (% lost to follow-up) | % cure | % cure/improved | N (%) positive & statistically significant outcomes |
---|---|---|---|---|---|---|
Pieber (1995) | 3 months | 21 | 8 (38) | 38.5 (1) | 84.5 (1) | NR |
PFMT+BF+ES+VW studies | Treatment time | N (subjects) | N (% lost to follow-up) | % cure | % cure/improved | N (%) positive & statistically significant outcomes |
---|---|---|---|---|---|---|
Parkkinen (2004) | 12 months | 19 | 2 (11) | NR a
| NR a
| 3 (100) |
Studies/arms of studies | Control group protocol | PFM action taught 1 = digital vaginal 2 = other | PFMT protocol (s/s) = Contraction time in seconds/relaxation time in seconds | Intensity of contract-ions or type of PFM T | Adjunct-ive therapy | Adjunctive therapy protocol | Duration of inter-vention | N of treat-ments (individual unless other-wise stated) |
---|---|---|---|---|---|---|---|---|
Aksac 2003 PFMT | 1 | 5s/10s, 10 reps, 3 sets/day. After 2 weeks, 10s/20s relax. Weekly individual sessions. | NR. Relaxation of abdominals, gluteals | 8 weeks | 8 | |||
Aksac 2003 PFMT+BF | 2 | 10s/20s, 40 reps, 3 sets/week. Weekly individual sessions. | NR | EMG vaginal BF to learn action only | No home training with BF. | 8 weeks | 8 | |
Aksac 2003 Control group | No PFMT | NA | ||||||
Arvonon 2001 PFMT | NA | 1 | 5s/5s, 10 reps (max), seated/standing, 2 sets/day. 3s/3s, 15 reps, (submax) 1 set/day 2 min. sustained (submax) 1 rep, 1 set/day. 3 clinic visits | Maximal, submaximal | 4 months | 3 | ||
Arvonon 2001 PFMT+VW | NA | 1 | a/a | VW | VW (50 g, 65 g, 80, 100 g) 20s/20s, (max) 10 reps, standing, 2 sets/day. 15 mins. VW with daily activities, gymnastics. | 4 months | 3 | |
Balmforth 2004 PFMT+BF | NA | 2 Perineal ultrasound | Intensive + individualised PFMT + 'behavioural modification' program Home program: NR | NR | Perineal ultrasound to teach correct contraction. Pre-treatment only. | 14 weeks | NR | |
Berghmans 1996 PFMT | NA | 1 | 3–30s contractions, 10–30 reps, supine/standing/all fours. PFE with coughing, stairs, lifting, jumping. Home: 3x/day. | NR | 4 weeks | 12 | ||
Berghmans 1996 PFMT+BF | NA | 1 | a/a | NR | EMG vaginal BF Clinic only. | Individual program for 12 sessions. | 4 weeks | 12 |
Bidmead 2002 PFMT | NR | 'Conventional 'PFE by experienced research physiotherapist. Home: details NR | NR | 14 weeks | NR | |||
Bidmead 2002 PFMT+ES | NR | ES (no details reported) | Same PFE program with home ES | 14 weeks | NR | |||
Bidmead 2002 Control group | No treatment | |||||||
Bo 1999 PFMT | 1 | 6–8s/6 s, 8–12 reps, 3–4 fast contractions at end of 'hold', 3 sets/day. Weekly group sessions with ex in different positions and for abdominals, back, thighs. Monthly PFM assessment. | High intensity | 6 months | 24 group 6 individual | |||
Bo 1999 Control group | No contact. Offered Continence Guard | |||||||
Bo 2000 PFMT | NR | As for Bo 1999 | 6 months | 24 group 6 individual | ||||
Bo 2000 Control group | No contact Offered use of Continence Guard | |||||||
Cammu & van Nylen 1998 PFMT+BF | NA | 1 | 'Brief' + 10s contractions, 10 reps, as many sets as possible 'within patients capacity'. Home: Increasing number of sets | Maximal | BF vag EMG + 'abdominal' EMG to reduce Valsalva efforts | Individual: Weekly, 30 min BF session | 12 weeks | 6 |
Chen 1999 PFMT+ES | NA | 1 | No details. 15 mins 2 sets/day, 3 months Then 15 mins/day, 1 set/day, 21 months | ES intravaginal, home stimulator | Increasing tx times: 20,40, 60 min, 2/week, 3 months. Biphasic square wave, 25 Hz. | 3 months (ES) 24 months (PFE) | 24 + 6 | |
Dumoulin 2004 PFMT+ES+BF | NR | Standardised reeducation program. Home: 5 days/week: no details. Weekly individual sessions | Strength & motor learning | 1. ES vag 2. BF vag EMG. Clinic only | 1. ES:15 mins 6s on/18s off, weeks 1–4, 8s on/24s off, weeks 5–8. 50 Hz, 250 msec. 2. BF 25 min | 8 weeks | 8 | |
Dumoulin 2004 PFMT+ES+BF+ abdominal exercises | NR | a/a Additional weekly 30 min session with deep abdominal muscle training | a/a | a/a | a/a | 8 weeks | 8 + 8 group sessions for abdominal muscle training | |
Dumoulin 2004 Control group | weekly massage with PT | 8 weeks | ||||||
Dumoulin 1995 PFMT+BF+ES | NA | 1 | 5s/10 s, 10 reps, 2 sets Home: 4 sets/day Individual session with ES/BF 3x/week. | Maximal | 1. ES Interferential current 4 suction electrodes 2. BF vag pressure Clinic only | 1. ES 15 mins 10–50 Hz, 15 mins 50 Hz. 2. BF 15 mins | 3 weeks | 9 |
Finkenhagen 1998 PFMT | NA | 1 | 6–8 s/6 s, 8–12 reps, 3–4 fast contractions at end of 'hold'. Home: 8–12 reps, 3 sets/day. Weekly exercise class (protocol as for Bo 1999) | Strength | 6 months | 1 individual + 24 group training | ||
Glavind 1996 PFMT | NA | 1 | 'standard procedure' – no details given. Individual sessions 2–3 times | NR | 4 weeks | 2–3 | ||
Glavind 1996 PFMT+BF | NA | NR | 5–10s contractions, 10 reps in supine, sitting, standing, Individual instruction | NR | BF vag EMG + rectal pressure BF to avoid IAP rise | 4 weekly sessions. Clinic only. | 4 weeks | 6–7 |
Hay-Smith 2004 PFMT a
| NA | NR | PFMT :motor relearning alone Home: no details | Motor learning | 20 weeks | 4 + 3 phone calls | ||
Hay-Smith 2004 PFMT b
| NA | NR | PFMT: strengthening plus motor relearning. Home: no details | Strength & motor learning | 20 weeks | 4 + 3 phone calls | ||
Johnson 2001 PFMT (SVC) +BF | NA | 2. Vaginal perineo meter | 10 s/10s, 15 minutes, submaximal (60% of MVC). 3 sets/day | Submaximal VoluntayContractions | BF vag pressure. Rectus EMG BF for first instruct ion | BF home training | 6 weeks | 2 |
Johnson 2001 PFMT (NMVC) +BF | NA | 2. Vaginal perineo meter | 10s/10s, 10 minutes, near-maximal (90% of MVC). 3 sets/day | Near-maximal Voluntary Contract ions | BF vaginal pressure Home trainer | 6 weeks | 2 | |
Knight 1998 PFMT+BF | NA | 1 | Up to 10s/4s (individualised), fast (up to 10), up to 10 reps, 6 sets a day. 6–18 months:1 set/day | Maximal | BF vaginal pressure. Home trainer + clinic. | Home trainer: 1 set PFX per day. Clinic: weekly for 1 month, then bi-weekly. 6–18 months: BF 1/week | 6 months | 14 |
Knight 1998 PFMT+BF+ES (home) | NA | 1 | a/a | Maximal | As for PFMT+BF plus ES (home) | Vaginal, overnight, 10 Hz, 200 ms. 5 on/5 off. Low intensity. 6–18 months: BF 1/week | 6 months | 14 |
Knight 1998 PFMT+BF+ES (clinic) | NA | 1 | a/a | Maximal | As for PFMT+BF plus ES (clinic) | Vaginal, 16 × 30 min., 35 Hz, 250 ms. 5 on/5 off. High intensity, contraction with stimulator. 6–18 months: BF 1/week | 6 months | 14 PFMT+BF 16 ES |
Miller 1998 PFMT | NA | 1 | Taught to contract and cough. Home practice. | Motor learning | 1 week | 2 | ||
Morkved 2002 PFMT | NA | 1 | 6–8s/6 s, 8–12 reps (high intensity). 3–4 fast contractions at end of 'hold. Home: 3 sets/day. Individual sessions | High intensity | 6 months | 16 | ||
Morkved 2002 PFMT+BF | NA | 1 | a/a with home BF. Individual sessions | High intensity | BF vaginal pressure home trainer | 6–8s/6 s, 8–12 reps (high intensity). 3–4 fast contractions at end of 'hold', 3 sets daily | 6 months | 16 |
Pages 2001 PFMT | NA | 1 | Group 5/week. Home: 100 reps/day during daily activities. Supine 10 mins, 2 sets/day. Group: different positions | 'Isolated' contractions, intensity NR. | 4 weeks group then 2 months home PFMT | 3 individual + 20 group | ||
Pages 2001 PFMT+BF | NA | 1 | 1 group session, individual BF training 15 mins, 5/week/4 weeks. Home: 10 reps, 4 sets, 5 times/week | NR | BF vaginal pressure. Clinic only | 15 min sessions Supine 10 reps/4 sets | 4 weeks individual then 2 months home PFMT | 23 individual |
Parkkinen 2004 PFMT+ES+BF+VW | NA | 1 | Short, low-intensity, 8–10 reps. High intensity: 5s/10s, 5 reps, low intensity: 20–30s/40–60s, 5 reps, supine & standing. Contract & cough. Home: 2 sets/day, 5 days/week | High intensity | 1. BF vag EMG 2. ES interferential 5–10 mins 50 Hz, 5–10 mins 10–50 Hz Clinic only. 3. VW | 1. BF 2. ES 10 mins 3. VW (20–80 g), 30 min/day, 5 days/week, during daily activities | Weekly to one year. Duration individual-ised: 'until desired outcome achieved' | 9 (3–29) |
Parkkinen 2004 PFMT+VW | NA | 1 | a/a | a/a | VW | VW (20–80 g), 30 min/day, 5 days/week, during daily activities | 12 months. | 3 |
Pieber 1995 PFMT+BF | NA | 1,2 Perineal ultrasound | Contract-relax times NR. 100 PFX per day. Encouraged to do the 'knack'. Individualised home program | Intensity NR. Relaxation of abdominals, gluteals, thighs | BF: Perineal ultra-sound (3 times). Clinic only | BF: Visualised PF on screen (3 sessions) | 3 months | 2–4 weekly intervals, 3 (asses ment) |
Pieber 1995 PFMT+BF+VW | NA | 1 | a/a | a/a | 1. BF: Perineal ultra-sound. Clinic only 2. VW | 1. Visualised PF on screen (3 sessions) 2. VW (20–70 g) 15 mins during daily activities | 3 months | a/a |
Sung 2000 PFMT | Explanation, no treatment | NR | PFM exercises 'as developed by Bo', details NR. Exercises in clinic with video. Home: same exercises, details NR | Intensive | 6 weeks | 6 | ||
Turkan 2005 PFMT+ES | NA | 2 (not clearly reported) | 5s contractions, 10 reps, 5 sets/day, 5 sets added in each week. Home: also with activities of daily living, provocation | Maximum intensity | ES -Interferential, 4 vacuum electrodes Clinic only | 10 mins each 0–10 Hz, 0–100 Hz. Voluntary contractions with ES | 5 weeks | 15 |
Wong 2001 PFMT+BF | NA | NR | Home: NR | Fast: maximal Slow: as long as possible. | BF vag EMG | 5 sets: 'fast'/10s rest: 3 reps, 'slow'/1 min rest: 2 reps. with BF. Clinic only | 4 weeks | 4 |
Wong 2001 PFMT+BF+ abdominal EMG BF | NA | NR | a/a | a/a | BF vag EMG & EMG BF-rectus abdominis Clinic only | a/a with abdominal EMG BF to minimise rectus activity | 4 weeks | 4 |
• Pelvic floor muscle training
• Biofeedback
• Electrical stimulation
• Vaginal weights
Types of outcomes
Studies | C1 | C2 | C3 | C4 | C5 | % subjects proceeding to surgery | No serious adverse events reported |
---|---|---|---|---|---|---|---|
Aksac (2003) | 1 | 1 | 1 | ||||
Arvonen (2001) | 1 | 1 | 1 | ||||
Balmforth (2004) | 1 | 1 | 2 | ||||
Berghmans (1996) | 1 | 2 | 1 | 1 | |||
Bidmead (2002) | 1 | 1 | 1 | ||||
Bo (1999) | 3 | 3 | 1 | 1 | yes | ||
Bo (2000) | 1 | ||||||
Cammu & van Nylen (1998) | 2 | 3 | 1 | 1 | 17 | yes | |
Chen (1999) | 2 | 1 | yes | ||||
Dumoulin (1995) | 1 | 1 | 1 | ||||
Dumoulin (2004) | 1 | 1 | 1 | 2 | yes | ||
Finkenhagen (1998) | 1 | ||||||
Glavind (1996) | 1 | 1 | yes | ||||
Hay-Smith (2002) | 1 | 2 | |||||
Johnson (2001) | 1 | 2 | 1 | ||||
Knight (1998) | 1 | 1 | 1 | ||||
Miller (1998) | 1 | ||||||
Morkved (2002) | 2 | 2 | 1 | 1 | 4.3–6.3 | yes | |
Pages (2001) | 1 | 1 | |||||
Parkkinen (2004) | 1 | 1 | 1 | 10.5 | yes | ||
Pieber (1995) | 1 | 0 | |||||
Sung (2000) | 1 | ||||||
Turkan (2005) | 1 | 3 | 1 | ||||
Wong (2001) | 1 | 2 | 1 | 1 |
Psychometric properties
Outcomes in terms of cure/improvement
Definitions of cure | Studies | Definitions of Improvement | Studies |
---|---|---|---|
Less than 1 g loss on pad test | Parkkinen (2004), Dumoulin (1995) | Decrease of 50% or more in pad weight | Aksac (2003) |
1 g or less on pad test | Aksac (2003) Glavind (1996) | Self-report of less urine loss compared with pre-treatment | Pieber (1995) |
Less that 2 g loss on pad test (st.b.vl) | Dumoulin (2004) Knight (1998) | Self-report: continent (cured), almost continent (improved) (5 point Likert scale) | Bo (1999) |
2 g or less on stress test (st.b.vl) | Bo (1999) Morkved (2002) | Rare or minor incontinence on exertion & 'satisfied' | Chen (1999) |
Self-report: unproblematic (5 point Likert scale) | Bo (1999) Morkved (2002) | Decrease of > 50% in IE & decrease in 'symptoms' | Pages (2001) |
'No incontinence' (measure NR) & no incontinence on UDS | Chen (1999) | Greatly improved: >75% improvement on pad test | Knight (1998) |
No incontinence for 7 days | Johnson (2001) | ||
No urine loss on any occasion & negative stress test | Pieber (1995) | ||
No urine loss on paper towel test | Miller (1998) |
Other outcomes
1. What is the evidence for PFMT, either alone or in combination with adjunctive therapies, when considering all treatment protocols, for the treatment for SUI in women, in the short and medium terms (up to 12 months after treatment)?
1.1 PFMT alone
1.2 PFMT with BF
1.3 PFMT with ES
1.4 PFMT with VW
1.5 PFMT with BF/ES
1.6 PFMT with BF/VW
1.7 PFMT with BF/ES/VW
1.8 Length of follow up
2. What is the evidence for different types of PFMT?
Strength training
• Effect of strength training on incontinence outcomes
• Effect of strength training on PFM strength
Skill training
Combination strength & skill training
Role of abdominal muscles
3. What other reported factors could affect outcome of physical therapy?
Age
Initial severity of incontinence
Compliance with the training program
Initial pelvic floor muscle strength
4. What is the evidence for the optimal period of treatment and number of treatments?
Duration of treatment period
Number of treatments
Response time
5. What is the evidence for the effectiveness of physical therapy in the clinical setting?
Generalisability of findings to clinical practice settings
Discussion
Question 1: What is the evidence for PFMT, either alone or in combination with adjunctive therapies, when considering all treatment protocols, for the treatment for SUI in women, immediately and up to 12 months after treatment?
Factors not assessed by the studies which could affect outcome
Outcome measures
Question 2: What is the evidence for different types of PFMT?
Question 3: What other reported factors could affect outcome of physical therapy?
Age
Initial severity of incontinence
Compliance with the home training program
Initial PFM strength
Question 4: What is the evidence for the optimal period of treatment and number of treatments?
Question 5: What is the evidence for the effectiveness of physical therapy in clinical practice settings and can the findings in the research settings be generalised to clinical practice?
Conclusion
Implications for practice
-
There was strong evidence that PFMT alone, with BF and with ES/BF is effective for women with SUI, with expected rates of cure up to 73% and cure/improvement up to 97%.
-
There was strong evidence for strength training of the PFM to reduce symptoms of SUI and to improve PFM strength.
-
Changes in incontinence outcomes were demonstrated after treatment duration of one week to six months, but improvements in PFM strength may require at least 3 months of specific strength training.
-
No benefit was found in this review in adding BF, ES or abdominal muscle training to a PFMT protocol. However, it is likely that these interventions still have a place in clinical practice as adjuncts to PFMT in particular populations of women.
-
Strength PFMT protocols were effective in younger and mid-aged women, but there was scant evidence on strength training in older women.
-
Evidence for skill training was found, especially if combined with strength training in women of all ages, but the optimal specific training protocol for skill training is unclear.
-
Women with different severity of symptoms and initial PFM strength require different training programs and protocols. Women with weaker initial PFM strength and more severe symptoms may have the greatest percentage improvement in symptoms.
-
Subjects using BF or ES as home treatment may be less compliant with a treatment program than women performing PFMT alone.
-
No serious adverse events have been reported with physical therapy.
Implications for research
-
economic outcomes as none have been reported
-
the effectiveness of physical therapy in routine clinical practice settings
-
the external validity of RCTs. Future studies should more adequately describe the setting for the intervention, expertise of person delivering the treatment, the source and characteristics of subjects
-
the longer term outcomes of physical therapies
-
programs and protocols appropriate for different subgroups of women eg women of different ages and with different severity of incontinence
-
the factors which influence a subject's likelihood of attending appointments, continuing with treatment and complying with the home training program
-
the optimal length of an episode of care
-
a more standardised approach to outcome measurement in research with appropriate outcome measures reflecting clinical practice requirements
-
an optimal minimum set of common outcome measures relevant to research and clinical practice settings